Pfizer Inc Says Commercial Transition Will Begin In November 2023, As U.S. Government Begins To Discontinue Distribution Of EUA-Labeled Paxlovid
Portfolio Pulse from Benzinga Newsdesk
Pfizer Inc has announced that the commercial transition of Paxlovid will begin in November 2023, as the U.S. government starts to discontinue distribution of EUA-labeled Paxlovid.
October 13, 2023 | 8:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's announcement of the commercial transition of Paxlovid starting from November 2023 could potentially impact its revenues and stock price.
The news directly pertains to Pfizer and its product Paxlovid. The commercial transition could potentially impact Pfizer's revenues and stock price, depending on the market's reaction and the success of the transition. However, the impact is not immediate as the transition will begin in November 2023.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100